What used to be illegal party drugs, then LA elite-only psychedelic therapies, are making their way into the research lab, mainstream medicine and now the workplace. A study in last month’s Journal of the American Medical Association reported that after researchers administered the psychedelic drug, psilocybin, in a single-dose, randomized clinical trial, it resulted in a significant reduction in depression among the participants. And there’s more. A burgeoning body of research shows that the trance-induced effects of the psychedelic, ketamine—used in conjunction with psychotherapy—has significant mental health benefits.
